Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease

@article{Liu2015NeuroprotectiveEO,
  title={Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease},
  author={W P Liu and Jaishree Jalewa and M. Sharma and G. Li and L. Li and Christian H{\"o}lscher},
  journal={Neuroscience},
  year={2015},
  volume={303},
  pages={42-50}
}
Neuroprotective Effects of a Cholecystokinin Analogue in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Parkinson’s Disease Mouse Model
TLDR
The present results indicate that CCK analogue shows a promising potential for the treatment of PD by activating the cAMP/PKA/CREB pathway that also inhibits apoptosis and regulates autophagy impairment.
A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson’s disease by reducing chronic inflammation in the brain
TLDR
The neuroprotective effects of a novel dual agonist (DA-JC1) in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease (PD) shows promise as a novel treatment of PD.
Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson’s disease
TLDR
The data suggest that post-treatment with PT302 provides long-lasting Exendin-4 release and reduces neurodegeneration of nigrostriatal dopaminergic neurons in a 6-hydroxydopamine rat model of PD at a clinically relevant dose.
The GLP-1 receptor agonist, liraglutide, fails to slow disease progression in SOD1G93A and TDP-43Q331K transgenic mouse models of ALS
TLDR
Overall, it is found that there is no evidence to support clinical evaluation of liraglutide as a potential candidate for the treatment of ALS.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 38 REFERENCES
Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases.
TLDR
GLP-1 mimetics show great promise as a novel treatment for neurodegenerative conditions because of the substantial body of evidence that these mimetics have neuroprotective and anti-inflammatory effects.
Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease.
TLDR
It is shown that, in the mouse MPTP PD model, systemic administration of exendin-4 significantly attenuates the loss of substantia nigra pars compacta neurons and the striatal dopaminergic fibers and suggests that exendIn-4 may be a valuable therapeutic agent for neurodegenerative diseases such as PD.
Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease
TLDR
The apparent ability of EX-4 to arrest progression of, or even reverse nigral lesions once established, suggests that pharmacological manipulation of the GLP-1 receptor system could have substantial therapeutic utility in PD.
Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis
TLDR
The results suggest that these novel incretin analogues cross the blood brain barrier and show physiological activity and neurogenesis in the brain, which may be of use as a treatment of neurodegenerative diseases.
MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease.
The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease
TLDR
In APP/PS1 mice, liraglutide prevented memory impairments in object recognition and water maze tasks, and prevented synapse loss and deterioration of synaptic plasticity in the hippocampus, commonly observed in this model, suggesting that GLP-1 analogs represent a novel treatment strategy for Alzheimer's disease.
Neuroprotective Effects of Liraglutide for Stroke Model of Rats
TLDR
This is the first study to demonstrate neuroprotective effects of liraglutide on cerebral ischemia through anti-oxidative effects and VEGF upregulation on a rat stroke model.
...
1
2
3
4
...